Existem quatro tipos principais de hemocromatose.[4]Kowdley KV, Brown KE, Ahn J, et al. Correction: ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Dec;114(12):1927.
http://www.ncbi.nlm.nih.gov/pubmed/31724994?tool=bestpractice.com
[7]Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.
https://journals.lww.com/ajg/fulltext/2019/08000/acg_clinical_guideline__hereditary_hemochromatosis.11.aspx
http://www.ncbi.nlm.nih.gov/pubmed/31335359?tool=bestpractice.com
A forma mais comum, tipo 1, é causada por mutações no gene HFE (regulador hemostático do ferro) e ocorre principalmente em pessoas de ascendência do norte da Europa.[2]Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999 Sep 2;341(10):718-24.
http://www.ncbi.nlm.nih.gov/pubmed/10471457?tool=bestpractice.com
[3]Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006 Aug 1;145(3):209-23.
http://www.ncbi.nlm.nih.gov/pubmed/16880463?tool=bestpractice.com
[4]Kowdley KV, Brown KE, Ahn J, et al. Correction: ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Dec;114(12):1927.
http://www.ncbi.nlm.nih.gov/pubmed/31724994?tool=bestpractice.com
[7]Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.
https://journals.lww.com/ajg/fulltext/2019/08000/acg_clinical_guideline__hereditary_hemochromatosis.11.aspx
http://www.ncbi.nlm.nih.gov/pubmed/31335359?tool=bestpractice.com
[8]European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. J Hepatol. 2022 Aug;77(2):479-502.
https://www.journal-of-hepatology.eu/article/S0168-8278(22)00211-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35662478?tool=bestpractice.com
[9]Olynyk JK, Ramm GA. Hemochromatosis. N Engl J Med. 2022 Dec 8;387(23):2159-70.
http://www.ncbi.nlm.nih.gov/pubmed/36477033?tool=bestpractice.com
Embora as estimativas precisas variem, a prevalência da hemocromatose relacionada ao HFE é semelhante nos EUA, na Europa e na Austrália, em aproximadamente 1 caso por 200 a 400 pessoas.[4]Kowdley KV, Brown KE, Ahn J, et al. Correction: ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Dec;114(12):1927.
http://www.ncbi.nlm.nih.gov/pubmed/31724994?tool=bestpractice.com
[7]Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.
https://journals.lww.com/ajg/fulltext/2019/08000/acg_clinical_guideline__hereditary_hemochromatosis.11.aspx
http://www.ncbi.nlm.nih.gov/pubmed/31335359?tool=bestpractice.com
[10]Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016 Aug 13;388(10045):706-16.
http://www.ncbi.nlm.nih.gov/pubmed/26975792?tool=bestpractice.com
A principal mutação do HFE (C282Y) é comum nos EUA: 1 em cada 10 indivíduos brancos é heterozigoto para essa mutação, enquanto aproximadamente 1 em cada 200 é um homozigoto para C282Y.[3]Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006 Aug 1;145(3):209-23.
http://www.ncbi.nlm.nih.gov/pubmed/16880463?tool=bestpractice.com
[11]Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005 Apr 28;352(17):1769-78.
http://www.nejm.org/doi/full/10.1056/NEJMoa041534#t=article
http://www.ncbi.nlm.nih.gov/pubmed/15858186?tool=bestpractice.com
A frequência da homozigosidade para C282Y é muito menor em outras etnias, incluindo pessoas hispânicas (0.27 por 1000), habitantes das ilhas do Pacífico (0.12 por 1000) e pessoas negras (0.14 por 1000).[3]Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006 Aug 1;145(3):209-23.
http://www.ncbi.nlm.nih.gov/pubmed/16880463?tool=bestpractice.com
[11]Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005 Apr 28;352(17):1769-78.
http://www.nejm.org/doi/full/10.1056/NEJMoa041534#t=article
http://www.ncbi.nlm.nih.gov/pubmed/15858186?tool=bestpractice.com
A mutação homozigótica C282Y está presente em aproximadamente 80% a 90% dos pacientes de origem do norte da Europa que têm hemocromatose do tipo 1.[2]Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999 Sep 2;341(10):718-24.
http://www.ncbi.nlm.nih.gov/pubmed/10471457?tool=bestpractice.com
[8]European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. J Hepatol. 2022 Aug;77(2):479-502.
https://www.journal-of-hepatology.eu/article/S0168-8278(22)00211-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35662478?tool=bestpractice.com
Mundialmente, a frequência dessa mutação pode variar, e outras mutações genéticas podem predominar.[12]Pérez R, Toro D, Fournier J, et al. Prevalence of hemochromatosis in the Puerto Rico veteran population. P R Health Sci J. 2007 Jun;26(2):147-50.
http://www.ncbi.nlm.nih.gov/pubmed/17722428?tool=bestpractice.com
[13]Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta. 2006 Jul;1763(7):700-10.
http://www.ncbi.nlm.nih.gov/pubmed/16891003?tool=bestpractice.com
[14]Terzić R, Sehić A, Teran N, et al. Frequency of HFE gene mutations C282Y and H63D in Bosnia and Herzegovina. Coll Antropol. 2006 Sep;30(3):555-7.
http://www.ncbi.nlm.nih.gov/pubmed/17058523?tool=bestpractice.com
[15]Cimburova M, Putova I, Provaznikova H, et al. S65C and other mutations in the haemochromatosis gene in the Czech population. Folia Biol (Praha). 2005;51(6):172-6.
http://fb.cuni.cz/Data/files/folia_biologica/volume_51_2005_6/FB2005A0030.pdf
http://www.ncbi.nlm.nih.gov/pubmed/16419611?tool=bestpractice.com
[16]Leone PE, Giménez P, Collantes JC, et al. Analysis of HFE gene mutations (C282Y, H63D, and S65C) in the Ecuadorian population. Ann Hematol. 2005 Feb;84(2):103-5.
http://www.ncbi.nlm.nih.gov/pubmed/15517265?tool=bestpractice.com
[17]Scotet V, Le Gac G, Mérour MC, et al. Impact of HFE genetic testing on clinical presentation of hereditary hemochromatosis: new epidemiological data. BMC Med Genet. 2005 Jun 1;6:24.
https://bmcmedgenet.biomedcentral.com/articles/10.1186/1471-2350-6-24
http://www.ncbi.nlm.nih.gov/pubmed/15929798?tool=bestpractice.com
[18]Pardo A, Quintero E, Barrios Y, et al. Genotype and phenotypic expression of hereditary hemochromatosis in Spain [in Spanish]. Gastroenterol Hepatol 2004 Oct;27(8):437-43.
http://www.ncbi.nlm.nih.gov/pubmed/15388046?tool=bestpractice.com
[19]Sassi R, Hmida S, Kaabi H, et al. Prevalence of C282Y and H63D mutations in the haemochromatosis (HFE) gene in Tunisian population. Ann Genet. 2004 Oct-Dec;47(4):325-30.
http://www.ncbi.nlm.nih.gov/pubmed/15581829?tool=bestpractice.com
[20]Wrede CE, Hutzler S, Bollheimer LC, et al. Correlation between iron status and genetic hemochromatosis (codon C282Y) in a large German population. Isr Med Assoc J. 2004 Jan;6(1):30-33.
https://www.ima.org.il/filesupload/imaj/0/51/25891.pdf
http://www.ncbi.nlm.nih.gov/pubmed/14740507?tool=bestpractice.com
[21]Milman N, Pedersen P, Steig T, et al. Frequencies of the hereditary hemochromatosis allele in different populations: comparison of previous phenotypic methods and novel genotypic methods. Int J Hematol. 2003 Jan;77(1):48-54.
http://www.ncbi.nlm.nih.gov/pubmed/12568299?tool=bestpractice.com
Por exemplo, no Equador, a frequência de C282Y foi relatada como 0%.[16]Leone PE, Giménez P, Collantes JC, et al. Analysis of HFE gene mutations (C282Y, H63D, and S65C) in the Ecuadorian population. Ann Hematol. 2005 Feb;84(2):103-5.
http://www.ncbi.nlm.nih.gov/pubmed/15517265?tool=bestpractice.com
As formas mais raras de hemocromatose (tipos 2-4), envolvendo mutações em outros genes, foram relatadas em todo o mundo.
Embora a hemocromatose do tipo 1 seja uma condição autossômica recessiva, com números aproximadamente iguais de homozigotos do sexo masculino e do sexo feminino, ela apresenta expressão clínica heterogênea, sendo mais comum em homens.[9]Olynyk JK, Ramm GA. Hemochromatosis. N Engl J Med. 2022 Dec 8;387(23):2159-70.
http://www.ncbi.nlm.nih.gov/pubmed/36477033?tool=bestpractice.com
Acredita-se que a perda de ferro por meio da menstruação e gravidez atenue manifestações da doença em mulheres homozigotas, embora outros fatores também possam estar envolvidos.[22]Anderson GJ, Bardou-Jacquet E. Revisiting hemochromatosis: genetic vs. phenotypic manifestations. Ann Transl Med. 2021 Apr;9(8):731.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106074
http://www.ncbi.nlm.nih.gov/pubmed/33987429?tool=bestpractice.com
Um grande estudo realizado com pacientes descendentes do norte da Europa (com idades entre 40 e 69 anos) mostrou que entre os homozigotos C282Y, doenças relacionadas à sobrecarga de ferro foram observadas em 28% dos homens e 1.2% das mulheres.[23]Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008 Jan 17;358(3):221-30.
http://www.nejm.org/doi/full/10.1056/NEJMoa073286#t=article
http://www.ncbi.nlm.nih.gov/pubmed/18199861?tool=bestpractice.com
O risco de doença clínica aumenta com a idade.[8]European Association for the Study of the Liver. EASL clinical practice guidelines on haemochromatosis. J Hepatol. 2022 Aug;77(2):479-502.
https://www.journal-of-hepatology.eu/article/S0168-8278(22)00211-2/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/35662478?tool=bestpractice.com
[24]Hagström H, Ndegwa N, Jalmeus M, et al. Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers. Liver Int. 2021 Mar;41(3):545-53.
https://onlinelibrary.wiley.com/doi/10.1111/liv.14792
http://www.ncbi.nlm.nih.gov/pubmed/33450138?tool=bestpractice.com
Na hemocromatose clássica, os sintomas tornam-se clinicamente aparentes na quarta ou quinta década de vida.